{
    "clinical_study": {
        "@rank": "18155", 
        "acronym": "Nabucco", 
        "arm_group": {
            "arm_group_label": "Adult female patients with MBC", 
            "description": "This is an observational study, no interventions are specified"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this non-interventional study is to collect data on the efficacy and safety\n      of Nab-Paclitaxel in the routine application."
        }, 
        "brief_title": "Non-interventional Study With Nab-Paclitaxel (Abraxane\u00ae)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The main focus of this non-interventional study is set on answering the following questions:\n\n        -  Can the results observed in controlled clinical trials regarding efficacy and safety be\n           reproduced in the routine clinical setting?\n\n        -  Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the\n           previously described safety-profile in terms of frequency and intensity?\n\n        -  What are the main reasons for modification or termination of the nab-paclitaxel\n           therapy?\n\n        -  How does nab-paclitaxel therapy influence the patients' quality of life?\n\n        -  What are the criteria for selecting nab-paclitaxel as therapy for metastatic breast\n           cancer?"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female Patients with metastatic breast cancer, who are at least 18 years old (no\n             upper age limit)\n\n        Exclusion Criteria:\n\n          -  Contraindication according to the summary of product characteristics of Abraxane\u00ae\n\n          -  No signed patient informed consent form available\n\n          -  pregnant or breastfeeding patients."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult female patients with metastatic breast cancer"
            }
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689610", 
            "org_study_id": "IOM-02240"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nab-Paclitaxel", 
            "Abraxane", 
            "Nabucco", 
            "safety", 
            "breast cancer", 
            "daily routine", 
            "peripheral neuropathy", 
            "iOMEDICO"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "info@iomedico.com", 
                "last_name": "iOMEDICO AG", 
                "phone": "+49 761 15 242", 
                "phone_ext": "0"
            }, 
            "facility": {
                "address": {
                    "city": "Freiburg", 
                    "country": "Germany", 
                    "state": "Baden-Wuerttemberg", 
                    "zip": "79108"
                }, 
                "name": "iOMEDICO AG"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Nabucco - Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "info@iomedico.com", 
            "last_name": "iOMEDICO AG", 
            "phone": "+49 761 15 242", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "Haemato-Onkologische Schwerpunktpraxis Franz-Schrank-Strasse 2 80638 Munich, Germany", 
            "last_name": "Christoph Salat, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to Tumor Progression (TTP)", 
            "safety_issue": "No", 
            "time_frame": "6 months after last-patient-in (LPI)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "6 months after last-patient-in (LPI)"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6 months after last-patient-in (LPI)"
            }, 
            {
                "measure": "Time to treatment discontinuation", 
                "safety_issue": "No", 
                "time_frame": "6 months after last-patient-in (LPI)"
            }, 
            {
                "measure": "Number of participants with Adverse Events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Until 30 days after discontinuation of Nab-paclitaxel"
            }, 
            {
                "measure": "Relative dosage of Nab-Paclitaxel", 
                "safety_issue": "No", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "measure": "Intensity of peripheral neuropathy", 
                "safety_issue": "Yes", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "measure": "Occurence of neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "measure": "Necessity of supportive medication (e.g. haematopoetic growth factors, analgetics, antibiotics and antiemetics)", 
                "safety_issue": "No", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "description": "Assessed by questionnaires FACT-G, FACT-B, FACT-Taxanes and a pain questionnaire of the Robert-Koch-Institute.", 
                "measure": "Patient reported outcome on Quality of life and adverse events", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 3 and 6 months after start of treatment"
            }, 
            {
                "measure": "Reasons for dose modifications or discontinuation of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "measure": "Occurence of febrile neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }, 
            {
                "measure": "Occurence of peripheral neuropathy", 
                "safety_issue": "Yes", 
                "time_frame": "Until discontinuation of Nab-Paclitaxel, up to 6 month"
            }
        ], 
        "source": "iOMEDICO AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "iOMEDICO AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}